JP Morgan Chase’s Elicio Therapeutics ELTX Stock Holding History

JP Morgan Chase’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.1K	Buy	7,680 +2,308	+43%	+$6.4K	﹤0.01%	7018
2026 Q2	$21.5K	Buy	+5,372	New	+$53.9K	﹤0.01%	6712
2025 Q2	–	Sell	-16	Closed	-$99	–	7232
2025 Q1	$99	Sell	16 -2	-11%	-$15	﹤0.01%	6874
2024 Q4	$88	Hold	18	–	–	﹤0.01%	7027
2024 Q3	$91	Buy	+18	New	+$80	﹤0.01%	7014
2022 Q2	–	Sell	-14,185	Closed	-$300K	–	6554
2022 Q1	$300K	Sell	14,185 -335	-2%	-$7.56K	﹤0.01%	4972
2021 Q4	$421K	Sell	14,520 -530	-4%	-$26.8K	﹤0.01%	4941
2021 Q3	$1.47M	Sell	15,050 -3,662	-20%	-$396K	﹤0.01%	4020
2021 Q2	$2.44M	Buy	18,712 +763	+4%	+$110K	﹤0.01%	3652
2021 Q1	$3.24M	Buy	+17,949	New	+$3.46M	﹤0.01%	3333

Other funds holding ELTX

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

JP Morgan Chase's ELTX Position: Q3 2026 in Review

JP Morgan Chase increased its Elicio Therapeutics (ELTX) stake by 43% in Q3 2026, buying an estimated $6.4K and bringing the position to 7,680 shares worth $14.1K. The position accounts for ﹤0.01% of the portfolio, ranked #7018.

JP Morgan Chase first reported a position in ELTX in Q1 2021 and has held it in 10 quarters since. The position peaked at $3.24M in Q1 2021. 57 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

JP Morgan Chase held 7,680 shares of Elicio Therapeutics worth $14.1K as of Q3 2026.
JP Morgan Chase bought 2,308 Elicio Therapeutics shares in Q3 2026, an estimated $6.4K.
Elicio Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #7018 holding.
JP Morgan Chase first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 10 quarters since.
JP Morgan Chase's Elicio Therapeutics position peaked at $3.24M in Q1 2021.
57 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.